| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.07. | QScreen AI Inc: QScreen AI adds tiered workplace screening system | 3 | Stockwatch | ||
| QSCREEN AI Aktie jetzt für 0€ handeln | |||||
| 20.07. | QScreen AI Inc.: QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability | 315 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture... ► Artikel lesen | |
| 14.07. | QScreen AI Inc: QScreen receives second U.S. patent | 2 | Stockwatch | ||
| 14.07. | QScreen AI Inc.: QScreen AI Secures Second US Patent, Extending Single-Camera Impairment Detection on Standard Hardware | 462 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection... ► Artikel lesen | |
| 26.06. | QScreen AI Inc: QScreen AI adopts semi-annual financial reporting | 3 | Stockwatch | ||
| 26.06. | QScreen AI Inc.: QScreen AI Announces Adoption of Semi-Annual Reporting | 540 | Newsfile | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform... ► Artikel lesen | |
| 25.06. | QScreen AI Inc: QScreen AI closes $243,820 first tranche of financing | 7 | Stockwatch | ||
| 25.06. | QScreen AI Inc.: QScreen AI Announces Close of First Tranche of Private Placement | 333 | Newsfile | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform... ► Artikel lesen | |
| 01.06. | QScreen AI Inc.: QScreen AI Launches European Investor Roadshow Following Recent Strategic and Technology Milestones | 410 | Newsfile | Toronto, Ontario--(Newsfile Corp. - June 1, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announced that... ► Artikel lesen | |
| 19.05. | QScreen AI Inc: QScreen AI appoints retired U.S. general as adviser | 7 | Stockwatch | ||
| 19.05. | QScreen AI Inc.: QScreen AI Appoints Former Pentagon Joint Artificial Intelligence Center Director Lt. Gen. Michael S. Groen (Ret.) to Advisory Board Following Live Platform Demonstration | 851 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announces the... ► Artikel lesen | |
| 06.05. | QScreen AI Inc.: QScreen AI Integrates Passive Voice Analysis into Multi-Signal Screening Platform - System Now Reads Physiological, Acoustic, and Behavioral Signals Simultaneously in Real Time | 512 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen"), today announced the full integration of a novel voice analysis engine into... ► Artikel lesen | |
| 04.05. | QScreen AI Inc: QScreen intake platform detects suicide risks | 1 | Stockwatch | ||
| 29.04. | QScreen AI Inc.: QScreen AI Appoints Former Union Pacific Vice President as Strategic Advisor to Drive Expansion into North American Rail and Transportation Markets | 469 | Newsfile | Veteran rail executive with 25 years of senior commercial relationships across North America's Class I railroads joins a platform that enables real-time identification of probable drug use from... ► Artikel lesen | |
| 27.04. | QScreen AI Inc: QScreen completes camera-based drug detection system | 3 | Stockwatch | ||
| 27.04. | QScreen AI Inc.: QScreen AI Completes Platform That Identifies Probable Drug a Person Has Consumed in Real Time from a Camera Alone - Targets Correctional Facilities Facing Coroner Scrutiny over Withdrawal Deaths | 427 | Newsfile | Patent-protected QAI Platform identifies the probable drug class - alcohol, opioids, benzodiazepines, stimulants, or cannabis from physiological camera data and simultaneously administers CIWA-Ar... ► Artikel lesen | |
| 26.02. | QScreen AI Inc.: QScreen AI Announces Strategic Financing to Advance Commercialization Initiatives Across North America | 691 | Newsfile | Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee... ► Artikel lesen | |
| 23.02. | QScreen AI Inc.: QScreen AI Advances Structured Commercial Discussions Following Canadian Trade Mission to Mexico | 402 | Newsfile | Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee... ► Artikel lesen | |
| 17.02. | QScreen AI treibt quanteninspirierte Optimierung mit US-Patentanmeldung voran und rückt durch nationale Berichterstattung auf CBC in den Fokus | 531 | IR-WORLD | TORONTO, 17. Februar 2026 - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FWB: 3QP), ein Innovator, der Quanten-KI-Technologien miteinander verbindet, um die
Screening-Methoden und das Wohlbefinden... ► Artikel lesen | |
| 17.02. | QScreen AI Inc.: QScreen AI Advances Quantum-Inspired Optimization with U.S. Patent Filing; Gains National Spotlight on CBC | 269 | Newsfile | Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,840 | -1,01 % | MARKET TALK/US-Gericht weist Antrag auf Verlegung von Bayer-Glyphosat-Vergleich ab | DJ MARKET TALK/US-Gericht weist Antrag auf Verlegung von Bayer-Glyphosat-Vergleich ab
Kläger gegen den Bayer-Konzern in den USA sind in der Berufungsinstanz mit dem Versuch gescheitert, die Zuständigkeit... ► Artikel lesen | |
| MERCK KGAA | 135,50 | -1,70 % | Aktien Frankfurt Ausblick: Dax knapp im Minus - Rutsch unter 21-Tage-Linie | FRANKFURT (dpa-AFX) - Für den Dax zeichnen sich nach dem schwachen Wochenauftakt am Dienstag weitere moderate Verluste ab. Eine Stunde vor Handelsbeginn signalisierte der X-Dax als außerbörslicher... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,350 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,340 | 0,00 % | Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data | ||
| ETON PHARMACEUTICALS | 59,98 | 0,00 % | PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M | ||
| NOVO NORDISK | 40,095 | -1,84 % | Novo Nordisk: Charttechnik! Aktie vor der Trendwende nach oben! | © Foto: Pavel Danilyuk auf Pexels (Symbolbild)Ein verlorenes Studienduell gegen Eli Lilly und eine Aktie, die schon seit Monaten unter Druck steht. Dennoch kommt gerade jetzt ein Chartsignal, das Hoffnungen... ► Artikel lesen | |
| OMNIAB | 4,740 | -0,21 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| LB PHARMACEUTICALS | 47,490 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming September Investor Events | ||
| ELI LILLY | 996,70 | -0,05 % | Milliarden für Zelltherapien, neue Regeln der FDA: Warum Eli Lilly, Johnson & Johnson und Mesoblast jetzt im Fokus stehen | ||
| GELTEQ | 0,889 | -0,53 % | Gelteq Limited: Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs | MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for... ► Artikel lesen | |
| KARDIGAN | 20,680 | 0,00 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 12,185 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy | Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further... ► Artikel lesen | |
| APNIMED | 27,980 | +0,61 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 68,09 | +0,10 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,205 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States | Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals... ► Artikel lesen |